Zdrowie i gospodarka · 28/07/2014
FDA Establishes Public Docket to Discuss Proprietary Name Reservation for Drug Products
The FDA is launching a public discussion on reserving proprietary names for drug products to reduce medication errors, following an agreement made during the 2007 reauthorization of the PDUFA IV.
Source: Federal Register — Food and Drug AdministrationOpen original release →